A method and a sensor for detecting L-arginine are provided. The method includes synthesizing ferrocene-functionalized hexadecapeptide dithiocyclopentane (FC-P16 Peptide), preparing a polypeptide composite membrane-modified electrode (FC-P16 Peptide/AuE), detecting L-Arg and other steps. The results show that the polypeptide composite membrane-modified electrode (FC-P16 Peptide/AuE) exhibits excellent electrochemical response properties to L-Arg. In 10 mmol/L phosphate-buffered saline (PBS, pH=7.4), the DPV response peak current of the polypeptide composite membrane-modified electrode has an excellent linear relationship with the L-Arg concentration of 1.0×10.sup.−13 mol/L to 1.0×10.sup.−7 mol/L, with a detection limit of 1.0×10.sup.−13 mol/L. With prominent reproducibility, repeatability and selectivity, the modified electrode has potential application in life science and nutritional health.

The present invention provides means and methods for functionalizing a polypeptide of interest at its C-terminus with an amino acid derivative.

The present invention discloses a method for preparing a PEGylated biomolecule with controllable binding sites, comprising: (1) PEGylating a biomolecule; (2) binding a barrier to at least one binding site in the PEGylated biomolecule; (3) separating the PEGylated biomolecule not bound to the barrier; and (4) separating the barrier and the PEGylated biomolecule bound thereto. In another aspect, the present invention discloses a method for preparing a PEGylated IL-2 with controllable binding sites, comprising: (1) PEGylating to couple a PEG with IL-2; (2) binding the PEGylated IL-2 to an IL-2α receptor; (3) separating the PEGylated IL-2 not bound to the IL-2α receptor; and (4) separating the IL-2α receptor and the PEGylated IL-2 bound thereto. By regulating the binding sites of IL-2, only 1 or 2 PEGs are added during PEGylation.

Provided are a GLP-1(7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.

Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

Provided herein are synthetic peptides with enhanced antimicrobial and antibiofilm characteristics, and are biocompatible with mammalian cellular systems. The disclosed synthetic antimicrobial moieties include a mastoparan peptide having SEQ ID NO:1 and a pentapeptide motif formed from phenylalanine, leucine, proline, and two isoleucine residues, wherein the pentapeptide motif is conjugated the N-terminus of the mastoparan peptide. Also provided are compositions comprising the synthetic peptides, as well as methods of treating a microbial infection or removing a biofilm using the peptides.

The disclosure is directed to compounds and methods for preparing purified macrocyclic peptide using “catch-release” methods. These methods comprise reacting a free amino group of a resin-bound linear peptide with an azide- or alkyne-functionalized cap to form a resin-bound capped linear peptide having an azide- or alkyne-functionalized cap; cleaving the capped linear peptide from the resin to form a free capped linear peptide having an azide- or alkyne-functionalized cap; reacting the free capped linear peptide having an azide-functionalized cap with an alkyne-functionalized catch resin, or reacting the free capped linear peptide having an akynyl-functionalized cap with an azide functionalized catch resin, to form a catch-resin bound capped linear peptide; reacting the catch-resin bound capped linear peptide under conditions sufficient to effect macrocyclization of the linear peptide and release of the macrocyclic peptide from the catch resin.

Provided herein are thiosuccinyl-crosslinked hemoglobin analogs useful as blood replacement agents, pharmaceutical compositions comprising the same and the methods of use and preparation thereof.

The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.

The present invention relates to peptide modifier compounds of Formula (1), or a salt thereof, wherein: a is an integer from 1 to 10, more preferably from 1 to 3; b is an integer from 0 to 7; Z is a terminal group and Y is a bivalent group. Further aspects of the invention relate to intermediates in the preparation of compounds of Formula (1), and the use of compounds of Formula 1 in the synthesis of peptide derivatives. ##STR00001##